| abstract |
The use of a compound of the formula I: (See formula) in which: m is an integer from 1 to 3; R 1 represents halogen or C 1-3 alkyl; R 2 is selected from one of the following three groups: 1) (C1-5) alkyl -R 3 (wherein R 3 is piperidin-4-yl which may have one or two substituents selected from hydroxy, halogen, C1 alkyl - 4, C1-4 hydroxyalkyl and C1-4 alkoxy; 2) (C2-5) alkenyl-R 3 (where R 3 is as defined herein); 3) (C2-5) alkynyl -R 3 (where R 3 is as defined herein); and wherein any alkyl, alkenyl or alkynyl group may have one or more substituents selected from hydroxy, halogen and amino; or a pharmaceutically acceptable salt thereof or a chemotherapeutic agent selected from: (i) another antiangiogenic agent that acts through a mechanism different from a compound of the formula I; (ii) a cytostatic agent; (iii) a biological response modifier; (iv) an antibody; and (v) an antiproliferative / antineoplastic drug and combinations thereof; in the manufacture of a medicament for use in the production of an antiangiogenic and / or reducing effect of vascular permeability in a warm-blooded animal, such as a human being. |